Global Petroleum (LON: GBP) says there is increased interest in farming-in to its PEL94 licence in Namibia. This would enable the exploitation of 2,747 million barrels of oil that is estimated to be on the licence. Other opportunities in the mineral resources sector are being assessed. The share price soared 123% to 0.145p. Sunda Energy […]

The post AIM movers: Global Petroleum talking to partners and Celadon Pharmaceuticals has not received cash appeared first on UK Investor Magazine.

Two companies leaving AIM were the best performers in the week. Chaarat Gold Holdings (LON: CGH) gained shareholder approval to leave AIM on Thursday. This is expected to happen on 16 August and there will be a matched bargains facility on Asset Match. Yet, the share price doubled to 0.23p, having more than doubled at […]

The post AIM weekly movers: Orchard Funding client in administration appeared first on UK Investor Magazine.

Tertiary Minerals (LON: TYM) says 86%-owned subsidiary Copernicus has singed a binding letter of agreement First Quantum Minerals, which could lead to a joint venture for the Mukai copper project in Zambia. First Quantum Minerals will spend a minimum of $1.5m on exploration over two years. After this, First Quantum Minerals can earn an initial […]

The post AIM movers: Tertiary Minerals potential Zambia joint venture and Kazera Global increases stakes appeared first on UK Investor Magazine.

Destiny Pharma (LON: DEST) shares continue to rise following the new data concerning its XF-73 treatment showing it significantly reduces post-surgical MRSA infections. This was a study of burn cases and XF-73 can reduce the risk of MRSA getting into the bloodstream and cause sepsis. Yesterday, Sir Nigel Rudd bought 1.24 million shares at 2.5p/share. […]

The post AIM movers: YouGov upgrades guidance and Orchard Funding’s largest customer in administration appeared first on UK Investor Magazine.

Destiny Pharma (LON: DEST) says that new data on its XF-73 treatment that shows it significantly reduces post-surgical MRSA infections. This was a study of burn cases and XF-73 can reduce the risk of MRSA getting into the bloodstream and cause sepsis. The share price improved 4.17% to 2.5p. FALLERS Unsurprisingly, UK Oil and Gas […]

The post AIM movers: Destiny Pharma data shows XF-73 effectiveness and UK Oil and Gas cash call appeared first on UK Investor Magazine.

Echo Energy (LON: ECHO) has raised £418,000 at 0.0025p each. The share price jumped 40.6% to 0.0045p/share. The convertible loan note deed has been terminated. The cash will fund initial production at the Tesoro gold concession and prepare for final investment decision on a tailings deposit project. Peterhouse is appointed as joint broker.   Unusually […]

The post AIM movers: Echo Energy funding Tesoro gold concession and Fadel Partners clients delay decision appeared first on UK Investor Magazine.

UK Oil and Gas (LON: UKOG) was the highest riser in the week following the ending of a convertible loan facility. Shore Capital has slightly reduced its stake to 12.8% The repayment of the convertible loan facility provided by RiverFort Global Opportunities and YA II PN means that the company is debt free. The share […]

The post AIM weekly movers: UK Oil and Gas debt free appeared first on UK Investor Magazine.

Investment company Mindflair (LON: MFAI) is still benefiting from the acquisition of investee company Landvault by AI company Infinite Reality. Landvault is valued at $450m in shares and is part of the portfolio of Sure Valley Ventures Fund, where MindFlair holds13%, plus a further 5.3% via its stake in Sure Ventures (LON: SURE). MindFlair’s share […]

The post AIM weekly movers: Mindflair discount narrows appeared first on UK Investor Magazine.

Shares in Destiny Pharma (LON: DEST) have made a modest recovery following yesterday’s announcement it intended to leave AIM. The largest trade was worth less than £6,000 and many of the trades are valued at less than £10. The share price improved 30.8% to 4.25p, but it is still 50% lower this week. A new […]

The post AIM movers: Spectra Systems bank contract and Chaarat Gold recapitalisation dependent on leaving AIM appeared first on UK Investor Magazine.

Timothy McCutcheon will replace Kirill Golovanov as chief executive of healthcare company Ovoca Bio (LON: OVB) and he has also bought his 19.5 million shares at 0.85p each. This follows Ovoca Bio’s decision to end the development of Orenetide after disappointing trial results. The company will assess new opportunities. The share price increased 37.1% to […]

The post AIM movers: OvocaBio getting new boss and Destiny Pharma leaving AIM appeared first on UK Investor Magazine.

Golden Metal Resources (LON: GMET) is undertaking high-resolution ground magnetic surveying at the Pilot Mountain project. A large magnetic anomaly has been identified and that could represent a potential buried porphyry system in depth. At the Garfield project geophysical work will help to delineate drill targets. Yesterday, Golden Metal Resources raised £506,250 at 22.5p/share from […]

The post AIM movers: Golden Metal Resources progresses survey work and Deltic Energy fails to find partner appeared first on UK Investor Magazine.

Data analysis and information publisher Merit Group (LON: MRIT) has conformed that it made a sharp improvement in profitability in the year to March 2024. Cost control and positive foreign exchange movements helped pre-tax profit reach £1.2m. A further improvement to £1.7m is expected for 2024-25. The share price increased 19.6% to 64p. Transport infrastructure […]

The post AIM movers: Merit profit recovery and ex-dividends appeared first on UK Investor Magazine.

Cancer diagnostics firm Angle (LON: AGL) has made its second positive announcement of the week. There are breakthrough results from DNA molecular analysis of cancer patient blood samples, and this covers many types of cancer. This proves the effectiveness of the Parsortix system combined with DNA analysis. Angle believes that using CTC-DNA testing of living […]

The post AIM movers: Angle DNA breakthrough and ex-dividends appeared first on UK Investor Magazine.

Craven House Capital (LON: CRV) investee companies Garimon and Honeydog – it has 29.9% of each company – are planning to reverse into the Amigo Holdings shell on the Main Market. These are music streaming and digital publishing businesses. The Craven House share price jumped 34.5% to 19.5 cents. Further positive data for antimicrobial drug […]

The post AIM movers: Shoe Zone beats expectations again and i-nexus Global loses client appeared first on UK Investor Magazine.

Mercantile Ports and Logistics Ltd (LON: MPL) has signed a five-year contract with Lucky Marine Shipping & Logistics to handle containers at the facility at Karanja in India. Volumes will build up over two years. Additional contracts are set to be signed for the facility. The share price improved 17.4% to 4.6p, but it is […]

The post AIM movers: Mercantile Ports contract and ex-dividends appeared first on UK Investor Magazine.

Trading recommenced in Caribbean-based oil and gas explorer Star Phoenix (LON: STA) shares following the appointment of a new auditor and publication of its annual report. The share price jumped 438% to 2.15p making the biggest riser on the week. Mark Tindall increased his stake in Zinnwald Lithium (LON: ZNWD) from 3.17% to 4.01%. The […]

The post AIM weekly movers: Destiny Pharma secures partner but discounted placing hits share price appeared first on UK Investor Magazine.

Subsea cable protection services provider Tekmar Group (LON: TGP) has won a contract to supply cable protection systems for the third phase of the Dogger Bank C wind farm in the North Sea. Delivery will start in the third quarter of 2024. Tekmar is already supplying the other phases. There is no news about the […]

The post AIM movers: Tekmar contract and ex-dividends appeared first on UK Investor Magazine.

Antimicrobial treatmentsdeveloper Destiny Pharma (LON: DEST) has been a very poor recommendation. The share price has slumped by more than two-thirds from 159.5p. The need for new antibiotics remains enormous and if any of the company’s treatments do gain approval, they will be highly valuable.   Getting to that point is important and that is […]

The post Tip update: Disappointing Destiny still has potential appeared first on UK Investor Magazine.

The share price of antimicrobial treatmentsdeveloper Destiny Pharma (LON: DEST) has done badly since the shares were recommended back in June. The key to the progress of the share price is likely to be positive news about the phase 3 trials for X-73, which prevents post-surgical infections, and c.diff prevention treatment NTCD-M3. The phase 2b […]

The post Tip update: Long-term prospects still huge for Destiny Pharma appeared first on UK Investor Magazine.

Small pharma companies tend to have one product or technology that could make them a highly successful investment. In some cases, there is a well advanced second treatment using different life sciences technology. This pharma company has a treatment to prevent serious infections that has already had highly positive phase 2b clinical study results. The […]

The post TIP: The AIM share preventing hospital infections appeared first on UK Investor Magazine.

There was a sharp rise in the share price of Destiny Pharma (LON: DEST) following the results of the phase 2b clinical study on the use of XF-73 nasal gel for the prevention of post-surgical infections. The shares have fallen back, and they remain attractive considering the potential for this antimicrobial treatment. The study covered […]

The post Destiny Pharma set for next phase appeared first on UK Investor Magazine.

Destiny Pharma (LON: DEST) expects to report on the study results of the phase 2b clinical study on the use of XF-73 nasal gel for the prevention of post-surgical infections by the end of March. finnCap believes that positive news would increase the broker’s valuation of Destiny by 80p a share. Destiny is a developer […]

The post Look out for XF-73 Destiny appeared first on UK Investor Magazine.

Clinical biotechnology firm Destiny Pharma plc (AIM:DEST) has seen its shares soar by more than 14% after the company announced it has received an £800,000 grant from the country’s leading innovation agency Innovate UK to help develop a novel, preventative treatment for COVID-19. The programme will see Destiny Pharma work alongside London-based biotechnology research company […]

The post Destiny Pharma receives grant for Covid-19 treatment, shares soar appeared first on UK Investor Magazine.